Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Arcoxia, Exxiv, Tauxib
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) of the coxib class. It selectively inhibits cyclooxygenase-2 (COX-2), an enzyme responsible for producing prostaglandins that mediate inflammation and pain. This selective inhibition reduces the risk of gastrointestinal side effects compared to traditional NSAIDs that inhibit both COX-1 and COX-2.
For the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and pain and signs of inflammation associated with chronic osteoarthritis.
Increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. Etoricoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Increased risk of serious gastrointestinal adverse events, including ulceration, bleeding, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms.
Outcome:
Increased bleeding risk
Mechanism:
Etoricoxib can displace warfarin from protein binding sites, increasing free warfarin levels.
Outcome:
Reduced etoricoxib absorption
Mechanism:
Antacids can alter the pH of the gastrointestinal tract, affecting etoricoxib absorption.
Outcome:
Increased risk of gastrointestinal irritation
Mechanism:
Additive irritant effects on the gastric mucosa.
Most likely new formulation: Extended-release formulation for improved patient compliance (2025, 60% confidence)
Based on current usage trends and safety profile, there is a low probability ( <5%) of regulatory changes impacting etoricoxib's availability in the next 5 years.
Nonsteroidal anti-inflammatory drug (NSAID), COX-2 inhibitor
Pyrazole